NCT02261103

Completed

Phase 1

A Multiple Dose Study With Increasing Pramipexole Doses (0.375 mg to 4.5 mg q.d.) of Oral Extended Release (ER) Tablets With a Three-way Cross Comparison of 4.5 mg Pramipexole ER q.d. Fasted Versus 4.5 mg Pramipexole ER q.d. Fed Versus 1.5 mg Pramipexole Immediate Release Tablets t.i.d. Fasted in Healthy Male Volunteers

Boehringer Ingelheim0 sites39 target enrollmentApril 2006

InterventionsPramipexole IR tablets Placebo matching Pramipexole ER tablets Pramipexole ER tablets Placebo matching Pramipexole IR tablets Standard high-fat breakfast

DrugsPramipexole ER tablets Pramipexole IR tablets Placebo matching Pramipexole ER tablets Placebo matching Pramipexole IR tablets

Overview

Phase: Phase 1
Intervention: Pramipexole IR tablets
Conditions: Healthy
Sponsor: Boehringer Ingelheim
Enrollment: 39
Primary Endpoint: Area under the concentration-time curve of the analyte in plasma over the time interval 0 to 4h at steady state (AUC0-4,ss) for ER
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The objectives of the studies are:

To demonstrate similar total exposure between pramipexole ER fasted and pramipexole ER fed after multiple administration of the highest daily dose of 4.5 mg q.d. and to reveal any food effect leading to uncontrolled release
To investigate the relative bioavailability of the ER-formulation of pramipexole in comparison to the IR-formulation at the highest daily dose of 4.5 mg after multiple dosing
To demonstrate dose proportionality between the dose strengths of the pramipexole ER formulation of 0.375, 0.75, 1.5, 3.0, and 4.5 mg after multiple daily (q.d.) dosing

Registry

clinicaltrials.gov

Start Date

April 2006

End Date

July 2006

Last Updated

11 years ago

Study Type

Interventional

Study Design

Crossover

Sex

Male

Investigators

Sponsor

Boehringer Ingelheim

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•All participants in the study should be healthy males
•Age range from 21 to 50 years
•Body mass index (BMI) be within 18.5 to 29.9 kg/m2
•In accordance with Good Clinical Practice and the local legislation all volunteers will have given their written informed consent prior to admission to the study

Exclusion Criteria

•Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
•Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
•Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
•History of orthostatic hypotension, fainting spells or blackouts
•Chronic or relevant acute infections
•History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
•Intake of drugs with a long half-life (\> 24:00 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study
•Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study
•Participation in another trial with an investigational drug (≤ one month prior to administration or during the trial)
•Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)

Arms & Interventions

Pramipexole IR, fasted

Pramipexole immediate release (IR) tablets

Intervention: Pramipexole IR tablets

Pramipexole IR, fasted

Pramipexole immediate release (IR) tablets

Intervention: Placebo matching Pramipexole ER tablets

Pramipexole ER, fasted

Pramipexole extended release (ER) tablets

Intervention: Pramipexole ER tablets

Pramipexole ER, fasted

Pramipexole extended release (ER) tablets

Intervention: Placebo matching Pramipexole IR tablets

Pramipexole ER, fed

Pramipexole extended release tablets with a high-fat meal 30 min before drug administration

Intervention: Pramipexole ER tablets

Pramipexole ER, fed

Pramipexole extended release tablets with a high-fat meal 30 min before drug administration

Intervention: Standard high-fat breakfast

Outcomes

Primary Outcomes

Area under the concentration-time curve of the analyte in plasma over the time interval 0 to 4h at steady state (AUC0-4,ss) for ER

Time Frame: up to 4 hours after drug application

Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ=0-24h (AUC0-24,ss) for ER

Time Frame: up to 23 hours after drug application on day 5

AUC0-24,ss for IR

Time Frame: up to 23 hours after drug application on day 5

Maximum measured concentration of the analyte in plasma at steady state (Cmax)

Time Frame: up to 23 hours after drug application on day 5

Secondary Outcomes

Peak-Trough Fluctuation (PTF)(up to 23 hours after drug application on day 5)
Terminal half-life of the analyte in plasma at steady state (t1/2,ss)(up to 23 hours after drug application on day 5)
Apparent volume of distribution during the terminal phase λz at steady state following extravascular administration (Vz/F,ss)(up to 23 hours after drug application on day 5)
Number of subjects with clinically relevant changes in laboratory parameters(up to 7 days after last drug administration)
Number of subjects with adverse events(up to 7 days after last drug administration)
Number of subjects with clinically relevant changes in vital signs(up to 7 days after last drug administration)
Amount of analyte that is eliminated in urine at steady state from the time point 0 to time point 24 (Ae0-24,ss)(up to 23 hours after drug application on day 5)
Amount of analyte that is eliminated in urine at steady state from the time point 0 to time point 8 (Ae0-8,ss) for IR(up to 8 hours after drug application on day 5)
Area under the concentration-time curve of the analyte in plasma over the time interval 0 to 8 h at steady state (AUC0-8,ss)(up to 8 hours after drug application)
Apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration (CL/F,ss)(up to 23 hours after drug application on day 5)
Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)(up to 23 hours after drug application on day 5)
Time from last dosing to the maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (tmax,ss)(up to 23 hours after drug application on day 5)
Predose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss)(predose on days 1 to 5)
Average concentration of the analyte in plasma at steady state (Cavg)(up to 23 hours after drug application on day 5)
Mean residence time of the analyte in the body at steady state after p.o. administration (MRTpo,ss)(up to 23 hours after drug application on day 5)
Renal clearance of the analyte at steady state determined over the dosing interval τ (CLR,ss)(up to 23 hours after drug application on day 5)
Assessment of global tolerability by investigator on a 4-point scale(day 5 of each visit)